NICE welcomes Office for Life Sciences new Blueprint to support innovative drugs

NICE welcomes Office for Life Sciences new Blueprint to support innovative drugs

NICE today welcomed the Office for Life Sciences new Blueprint to support the life sciences industry, which will also improve patient access to innovative new drugs.

Welcoming the Blueprint launch, Andrew Dillon Chief Executive of NICE said: "Securing a successful future for the life sciences industries is important for patients and the UK economy.The Innovation Pass is an opportunity for data to be gathered on potentially important new treatments. NICE has been involved in discussions about the Innovation Pass, and we are looking forward to continuing to play a key role in developing the pass."

Mr Dillon continued: "NICE is committed to engaging constructively with the pharmaceutical industry and we are extending the access that companies have to us, as we appraise their products. Later this year, we will begin asking pharmaceutical and other life sciences companies, whose products we are evaluating, to make technical staff available to engage with our advisory Appraisal Committees. They will be able to respond to requests from committee chairs to clarify the data they have submitted and to point out any error of fact in the presentation of their data. We believe that this will give companies more confidence in the way NICE handles the evaluation of their products."

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.